No RCC Recurrence in Patients Treated With Adjuvant Neoantigen Vaccine
A phase 1 study of a personalized cancer vaccine demonstrated antitumor immunity in all treated patients with resected renal cell carcinoma.
A phase 1 study of a personalized cancer vaccine demonstrated antitumor immunity in all treated patients with resected renal cell carcinoma.
Explore the latest findings from a real-world data analysis on the effectiveness of immunotherapy in treating metastatic biliary tract cancer (mBTC) with spe…
A renowned scientist @OSUCCC_James is building on a groundbreaking discovery that may lead to new treatments for cancer and inflammation.
Elias Jabbour, MD, discusses how advancements in the administration and sequencing of TKIs have improved long-term prognosis for patients with CML.
Exclusive: Shadow health secretary discusses plans for waiting lists and patient safety if Labour wins election
The addition of tafasitimab to lenalidomide and rituximab therapy demonstrates safety and efficacy for patients with relapsed/refractory follicular lymphoma, according to results from a phase…
The active ingredient in Journavx is suzetrigine, a sodium channel blocker.
Major Finding: Cancer cells transfer mitophagy-resistant mitochondria to tumor-infiltrating lymphocytes (TIL) that impair antitumor activity. Concept: Deubiquitinase USP30 protects cancer cell-derived mitochondria from ROS-induced mitophagy…
Abstract. Tumors utilize various mechanisms of HLA disruption in order to evade immune surveillance. Previous computational tools have interrogated specific aspects of this process, yet…
A Moffitt team member’s commitment to making every day count